Skip to main content

Medical disclaimer: This site is educational and does not provide individualized medical advice. Always consult a licensed clinician about your situation.

Life stage

Perimenopause

The menopausal transition, characterized by hormonal fluctuation and changing symptoms.

Hormonal fluctuation during the menopausal transition may affect weight, bone turnover, and vasomotor symptoms. Evidence specific to perimenopausal use of GLP-1 agonists, GnRH analogs, or PTH peptides is sparse; most trials classify participants by age rather than menopausal stage.

Evidence gaps and exclusion patterns

  • Hormonal interaction studies
  • Symptom endpoints

Questions for clinician conversations

  • What evidence exists for people in my life stage?
  • What are the known unknowns for this medicine in this population?
  • How should I monitor for adverse effects?

Author

Ian Gauntt

RN, BSN — 10 years as a critical care nurse

Medical reviewer

Medical Reviewer (Pending Assignment)

Medical review pending assignment by a licensed clinician.

Last reviewed 2026-08-01Next review 2026-11-01

Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.

The Women's Evidence Brief — one audit, one update, one evidence lesson each week.

Join the list